DoxorubicinAntibiotics, AntineoplasticVincristineAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDaunorubicinDrug ResistanceAntineoplastic AgentsNaphthacenesRazoxaneP-GlycoproteinLeukemia P388Drug Resistance, NeoplasmDrug Resistance, MultipleCell SurvivalVinblastineNogalamycinEtoposideLiposomesDrug CarriersPrednisoneBreast NeoplasmsDose-Response Relationship, DrugTumor Cells, CulturedCisplatinBleomycinCell Line, TumorLeukemia L1210Drug Administration ScheduleDrug SynergismPaclitaxelAclarubicinCombined Modality TherapySarcomaApoptosisNephrosisVerapamilCarubicinDrug Screening Assays, AntitumorPolyethylene GlycolsMitoxantroneMethotrexateIfosfamideFluorouracilTreatment OutcomeAnthracyclinesTime FactorsMechlorethamineCardiomyopathiesProcarbazineMitomycinNeoplasm TransplantationHeartOsteosarcomaAntineoplastic Agents, PhytogenicCardiotoxinsHydroxyethylrutosideDrug Delivery SystemsDNA DamageDisease-Free SurvivalLeukopeniaLeukemia, ExperimentalMenogarilDNA Topoisomerases, Type IISurvival AnalysisLung NeoplasmsMice, NudeHeart DiseasesMyocardiumMitomycinsDacarbazineTopoisomerase II InhibitorsCell LineAmsacrineInfusions, IntravenousIntercalating AgentsNeoplasms, ExperimentalAminoacridinesSoft Tissue NeoplasmsOvarian NeoplasmsEpirubicinCarcinoma, Small CellKB CellsBone NeoplasmsGenes, MDRCell DivisionHodgkin DiseaseTaxoidsChemotherapy, AdjuvantDactinomycinCytarabineProdrugsLymphoma, Non-HodgkinDrug EvaluationTumor Suppressor Protein p53Survival RateTissue DistributionNeoplasmsSemustineMelphalan